Showing 31-40 of 131 results for "".
- American Skin Association Names Almirall Distinguished Corporate Leaderhttps://practicaldermatology.com/news/american-skin-association-names-almirall-distinguished-corporate-leader/2459997/Almirall took home the Distinguished Corporate Leadership award by the American Skin Association (ASA). Ron Menezes, President and General Manager of Almirall LLC, accepted the award and spoke about Almirall's new corporate purpose which aligns with ASA’s mission to advance research, champion sk…
- Pilot Study: Regular Moisturization May Cut Dementia Riskhttps://practicaldermatology.com/news/pilot-study-regular-moisturization-may-cut-dementia-risk/2459971/Inflamed skin in older adults may contribute to a wide range of age-related conditions including heart disease and Alzheimer’s disease, but regular moisturization may cool the inflammation and lower disease risk in the process, according to a pilot study. In the study, 33 adults aged 58 and 95 app…
- Almirall's Seysara Now Availablehttps://practicaldermatology.com/news/seysara-now-available/2459932/SeysaraTM (sarecycline), a novel tetracycline-derived oral antibiotic developed specifically for the treatment of acne, is now commercially available from Almirall. Seysara™ was approved in October by FDA for the treatment of moderate to severe non-nodular inflammatory acne vulgaris in patients 9 y…
- Almirall, LLC is the New Name of Aquahttps://practicaldermatology.com/news/aqua-is-now-almirall/2457551/Almirall, LLC is the new name of Aqua Pharmaceuticals. Almirall, LLC is part of the larger Almirall, S.A. family, an internationally-recognized global dermatology pharmaceutical company, with a strong focus on skin health. The name change, was announced jointly by Almirall LLC President and General…
- Krystal Biotech: Positive Interim Results in Phase 1/2 Trial of KB103https://practicaldermatology.com/news/krystal-biotech-positive-interim-results-in-phase-12-kb103-trial/2457562/Krystal Biotech, Inc. has announced positive interim results from its ongoing placebo-controlled Phase 1/2 clinical trial of KB103. Two adult Recessive Dystrophic Epidermolysis Bullosa (“RDEB”), NC1[+] patients aged 35 and 28 years old have completed treatment with topical KB103 to date. The patie…
- Almirall to Acquire Allergan's US Medical Dermatology Unithttps://practicaldermatology.com/news/almirall-to-acquire-allergans-us-medical-dermatology-unit/2457661/Almirall is acquiring a portfolio of five products from Allergan’s Medical Dermatology unit in the United States, conditional to the clearance by the relevant authorities. The portfolio includes Aczone® (dapsone), Tazorac® (tazarotene), Azelex® (azelaic acid) and Cordran® Tape (fludroxycortide), as…
- Provectus Biopharmaceuticals Announces Leadership Changeshttps://practicaldermatology.com/news/provectus-biopharmaceuticals-announces-leadership-changes/2458674/Provectus Biopharmaceuticals, Inc. detailed several leadership changes following the resignation of one of its Co-Founders and its Chairman and CEO, H. Craig Dees, PhD. The Provectus Board of Directors accepted the resignation of Dr. Dees, which he submitted due to personal and health reasons, in a…
- Actelion Launches Valchlor to Treat Stage IA and IB Mycosis Fungoides-type Cutaneous T-cell Lymphomahttps://practicaldermatology.com/news/20131119-actelion_launches_valchlor_to_treat_stage_ia_and_ib_mycosis_fungoides-type_cutaneous_t-cell_lymphoma/2459409/The FDA approved Actelion's Valchlor (mechlorethamine), the first and only FDA-approved topical formulation of mechlorethamine. Valchlor, a gel that is applied topically once a day, is an alkylating drug indicated to treat patients with stage IA and IB mycosis fungoides-type cutaneous T-cell lympho…
- Grants Awarded from National Rosacea Societyhttps://practicaldermatology.com/news/20121127-grants_awarded_from_national_rosacea_society/2459673/The National Rosacea Society (NRS) awarded funding to five new studies as part of its research grants program to increase knowledge and understanding of rosacea. Dr. Anna Di Nardo, associate professor of medicine at the University of California-San Diego, received $25,000 to study the role of mast …
- San Diego Dermatology Symposium to Debut in Mayhttps://practicaldermatology.com/news/san-diego-dermatology-symposium-to-debut-in-may/2460254/Dermatology is a rapidly evolving specialty on the forefront of research and treatment advancements. With the advent of new advances in medical, cosmetic, and surgical dermatology, new clinical recommendations for diagnosis and treatment of various dermatologic conditions are developed. The San D…